company background image
FOLD

Amicus Therapeutics NasdaqGM:FOLD Stock Report

Last Price

US$12.32

Market Cap

US$3.5b

7D

1.1%

1Y

17.6%

Updated

14 Aug, 2022

Data

Company Financials +
FOLD fundamental analysis
Snowflake Score
Valuation5/6
Future Growth6/6
Past Performance0/6
Financial Health4/6
Dividends0/6

FOLD Stock Overview

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases.

Amicus Therapeutics Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Amicus Therapeutics
Historical stock prices
Current Share PriceUS$12.32
52 Week HighUS$12.76
52 Week LowUS$5.91
Beta0.96
1 Month Change13.55%
3 Month Change64.71%
1 Year Change17.56%
3 Year Change18.80%
5 Year Change-1.52%
Change since IPO-14.62%

Recent News & Updates

Aug 10

Amicus Therapeutics: AT-GAA Approval Delayed, I Will Continue Holding

Amicus Therapeutics' AT-GAA approval in Pompe Disease has been pushed back by 3 months. However, the stock seems buoyant enough. I will continue holding, taking profits where I can. In my previous coverage in May, I wrote the following desultory text: Amicus Therapeutics, Inc. (FOLD) stock is not able to get to its proper potential despite the company's excellence in running its business. Every time I revisit the company, I am astounded by the compelling thesis, the value-market mismatch, and the ensuing opportunity - and yet the stock fails to deliver. I am happy to report that the stock is up 50% since then, despite the FDA extending the review period "by 90 days for the Biologics License Application (BLA) for cipaglucosidase alfa and the New Drug Application (NDA) for miglustat, the two components of AT-GAA." The AT-GAA BLA is fraught with risk because the trial backing the BLA actually failed to meet the primary endpoint. However, here's what I said before about the PROPEL trial: …although PROPEL missed statistical significance in the combined population of patients for motor function, it achieved stat sig for lung function or FVC, which is the more critical symptom… The funny thing about both the COMET and PROPEL trials is that COMET's primary endpoint was FVC, and 6MWT was its secondary endpoint; in PROPEL, it was the other way round. 6MWT was the primary, and FVC was the secondary endpoint. The funny thing, as I was saying, is that COMET missed the FVC primary endpoint but did better with 6MWT; and PROPEL missed the 6MWT primary endpoint but did better with FVC. Now, Sanofi got an approval from the COMET trial, although it failed its primary endpoint. So I expect AT-GAA to be approved as well. More importantly, COMET failed FVC but got approval on secondary endpoint 6MWT. However, as I noted before, FVC is the more important cause of mortality in Pompe patients. Here, PROPEL met stat sig in FVC, despite failing in 6MWT, its primary endpoint. Thus, its chances of approval seem more than Sanofi's Nexviazyme. So why was the PDUFA delayed by 3 months? According to the press brief, they released on May 10: The FDA extended the PDUFA dates to allow additional time to review information submitted by the Company as part of its ongoing reviews. The extension of the review timeline was not related to requests for any additional clinical data. The Company also expects that the additional time will allow for the completion of the pre-license approval inspections necessary at the WuXi Biologics manufacturing site in China.

Aug 03

Amicus Therapeutics Q2 2022 Earnings Preview

Amicus Therapeutics (NASDAQ:FOLD) is scheduled to announce Q2 earnings results on Thursday, August 4th, before market open. The consensus EPS Estimate is -$0.22 (-15.8% Y/Y) and the consensus Revenue Estimate is $85.88M (+11.0% Y/Y). Over the last 1 year, FOLD has beaten EPS estimates 50% of the time and has beaten revenue estimates 100% of the time. Over the last 3 months, EPS estimates have seen 0 upward revisions and 3 downward. Revenue estimates have seen 1 upward revision and 8 downward.

Shareholder Returns

FOLDUS BiotechsUS Market
7D1.1%1.2%3.2%
1Y17.6%-21.7%-10.2%

Return vs Industry: FOLD exceeded the US Biotechs industry which returned -21.7% over the past year.

Return vs Market: FOLD exceeded the US Market which returned -10.2% over the past year.

Price Volatility

Is FOLD's price volatile compared to industry and market?
FOLD volatility
FOLD Average Weekly Movement8.5%
Biotechs Industry Average Movement12.6%
Market Average Movement7.7%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: FOLD is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: FOLD's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2002496Brad Campbellhttps://amicusrx.com

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development.

Amicus Therapeutics Fundamentals Summary

How do Amicus Therapeutics's earnings and revenue compare to its market cap?
FOLD fundamental statistics
Market CapUS$3.46b
Earnings (TTM)-US$280.99m
Revenue (TTM)US$321.15m

10.8x

P/S Ratio

-12.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
FOLD income statement (TTM)
RevenueUS$321.15m
Cost of RevenueUS$35.33m
Gross ProfitUS$285.82m
Other ExpensesUS$566.81m
Earnings-US$280.99m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.00
Gross Margin89.00%
Net Profit Margin-87.50%
Debt/Equity Ratio225.3%

How did FOLD perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is FOLD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for FOLD?

Other financial metrics that can be useful for relative valuation.

FOLD key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue11x
Enterprise Value/EBITDA-15x
PEG Ration/a

Price to Sales Ratio vs Peers

How does FOLD's PS Ratio compare to its peers?

FOLD PS Ratio vs Peers
The above table shows the PS ratio for FOLD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average20.4x
INSM Insmed
14.8x37.6%US$3.3b
PTCT Therapeutics
6.1x11.2%US$3.8b
BPMC Blueprint Medicines
18.7x41.1%US$4.3b
DNLI Denali Therapeutics
41.8x48.3%US$4.7b
FOLD Amicus Therapeutics
10.8x25.4%US$3.5b

Price-To-Sales vs Peers: FOLD is good value based on its Price-To-Sales Ratio (10.8x) compared to the peer average (20.4x).


Price to Earnings Ratio vs Industry

How does FOLD's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Sales vs Industry: FOLD is good value based on its Price-To-Sales Ratio (10.8x) compared to the US Biotechs industry average (17.2x)


Price to Sales Ratio vs Fair Ratio

What is FOLD's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

FOLD PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio10.8x
Fair PS Ratio11.6x

Price-To-Sales vs Fair Ratio: FOLD is good value based on its Price-To-Sales Ratio (10.8x) compared to the estimated Fair Price-To-Sales Ratio (11.6x).


Share Price vs Fair Value

What is the Fair Price of FOLD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: FOLD ($12.32) is trading below our estimate of fair value ($50.95)

Significantly Below Fair Value: FOLD is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies

Future Growth

How is Amicus Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 12 analysts?

Future Growth Score

6/6

Future Growth Score 6/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


71.5%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: FOLD is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).

Earnings vs Market: FOLD is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: FOLD is expected to become profitable in the next 3 years.

Revenue vs Market: FOLD's revenue (25.4% per year) is forecast to grow faster than the US market (7.9% per year).

High Growth Revenue: FOLD's revenue (25.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: FOLD's Return on Equity is forecast to be high in 3 years time (25.6%)


Discover growth companies

Past Performance

How has Amicus Therapeutics performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


2.6%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: FOLD is currently unprofitable.

Growing Profit Margin: FOLD is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: FOLD is unprofitable, but has reduced losses over the past 5 years at a rate of 2.6% per year.

Accelerating Growth: Unable to compare FOLD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: FOLD is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (24.5%).


Return on Equity

High ROE: FOLD has a negative Return on Equity (-162.02%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Amicus Therapeutics's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: FOLD's short term assets ($497.6M) exceed its short term liabilities ($164.6M).

Long Term Liabilities: FOLD's short term assets ($497.6M) exceed its long term liabilities ($462.5M).


Debt to Equity History and Analysis

Debt Level: FOLD's net debt to equity ratio (2.2%) is considered satisfactory.

Reducing Debt: FOLD's debt to equity ratio has increased from 59% to 225.3% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: FOLD has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if FOLD has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Discover healthy companies

Dividend

What is Amicus Therapeutics's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate FOLD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate FOLD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if FOLD's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if FOLD's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as FOLD has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

4.4yrs

Average management tenure


CEO

Brad Campbell (46 yo)

7.58yrs

Tenure

US$4,911,455

Compensation

Mr. Bradley L. Campbell, also known as Brad, MBA, serves as Director of Gennao Bio, Inc. since March 2022. He serves as Director of Alliance for Regenerative Medicine. He served as Chief Operating Officer...


CEO Compensation Analysis

Compensation vs Market: Brad's total compensation ($USD4.91M) is about average for companies of similar size in the US market ($USD6.53M).

Compensation vs Earnings: Brad's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: FOLD's management team is considered experienced (4.4 years average tenure).


Board Members

Experienced Board: FOLD's board of directors are considered experienced (5.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.2%.


Top Shareholders

Company Information

Amicus Therapeutics, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Amicus Therapeutics, Inc.
  • Ticker: FOLD
  • Exchange: NasdaqGM
  • Founded: 2002
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$3.456b
  • Shares outstanding: 280.50m
  • Website: https://amicusrx.com

Number of Employees


Location

  • Amicus Therapeutics, Inc.
  • 3675 Market Street
  • Philadelphia
  • Pennsylvania
  • 19104
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/14 00:00
End of Day Share Price2022/08/12 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.